A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer

M. J. Lind; S. Gomm; A. P. Simmonds; L. Ashcroft; A. Kamthan; H. Gurney; N. Thatcher

doi:10.1007/BF00689705

A phase II study of ifosfamide and a_2b-interferon in advanced non-small-cell lung cancer

M. J. Lind^*, S. Gomm, A. P. Simmonds, L. Ashcroft, A. Kamthan, H. Gurney, N. Thatcher

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

A total of 45 patients with advanced non-small-cell lung cancer were treated with a combination of 1.5 g/m² ifosfamide given on days 1-5 every 3 weeks for four courses with 3 million IU a_2b-interferon (Intron A) given s.c. three times a week for 12 weeks. Nine objective responses were seen, including two complete responses (CRs) and seven partial responses (PRs). Haematological and non-haematological toxicities were generally mild and did not necessitate discontinuation of therapy.

Original language	English
Pages (from-to)	142-144
Number of pages	3
Journal	Cancer Chemotherapy and Pharmacology
Volume	28
Issue number	2
DOIs	https://doi.org/10.1007/BF00689705
Publication status	Published - Mar 1991
Externally published	Yes

Access to Document

10.1007/BF00689705

Cite this

@article{a278562434da483f96d66587d17b60f5,

title = "A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer",

abstract = "A total of 45 patients with advanced non-small-cell lung cancer were treated with a combination of 1.5 g/m2 ifosfamide given on days 1-5 every 3 weeks for four courses with 3 million IU a2b-interferon (Intron A) given s.c. three times a week for 12 weeks. Nine objective responses were seen, including two complete responses (CRs) and seven partial responses (PRs). Haematological and non-haematological toxicities were generally mild and did not necessitate discontinuation of therapy.",

author = "Lind, \{M. J.\} and S. Gomm and Simmonds, \{A. P.\} and L. Ashcroft and A. Kamthan and H. Gurney and N. Thatcher",

year = "1991",

month = mar,

doi = "10.1007/BF00689705",

language = "English",

volume = "28",

pages = "142--144",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer, Springer Nature",

number = "2",

}

TY - JOUR

T1 - A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer

AU - Lind, M. J.

AU - Gomm, S.

AU - Simmonds, A. P.

AU - Ashcroft, L.

AU - Kamthan, A.

AU - Gurney, H.

AU - Thatcher, N.

PY - 1991/3

Y1 - 1991/3

N2 - A total of 45 patients with advanced non-small-cell lung cancer were treated with a combination of 1.5 g/m2 ifosfamide given on days 1-5 every 3 weeks for four courses with 3 million IU a2b-interferon (Intron A) given s.c. three times a week for 12 weeks. Nine objective responses were seen, including two complete responses (CRs) and seven partial responses (PRs). Haematological and non-haematological toxicities were generally mild and did not necessitate discontinuation of therapy.

AB - A total of 45 patients with advanced non-small-cell lung cancer were treated with a combination of 1.5 g/m2 ifosfamide given on days 1-5 every 3 weeks for four courses with 3 million IU a2b-interferon (Intron A) given s.c. three times a week for 12 weeks. Nine objective responses were seen, including two complete responses (CRs) and seven partial responses (PRs). Haematological and non-haematological toxicities were generally mild and did not necessitate discontinuation of therapy.

UR - https://www.scopus.com/pages/publications/0025890057

U2 - 10.1007/BF00689705

DO - 10.1007/BF00689705

M3 - Article

C2 - 1647893

AN - SCOPUS:0025890057

SN - 0344-5704

VL - 28

SP - 142

EP - 144

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 2

ER -

A phase II study of ifosfamide and a_2b-interferon in advanced non-small-cell lung cancer

Abstract

Access to Document

Other files and links

Fingerprint

Cite this